Moderna and Merck mRNA Cancer Vaccine Hits Primary Phase 3 Trial Endpoint
Moderna and Merck announced on August 19, 2026, that their personalized melanoma vaccine, intismeran, combined with Keytruda, successfully met its goals in a Phase 3 trial of…